Sam Murphy

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Go Therapeutics, Inc. manufactures and develops cancer therapeutics. The company was founded by Constantine Theodoropulos and is headquartered in Cambrige, MA.

M.A. Med Alliance SA is a company based in Nyon, Switzerland that specializes in developing innovative technology and commercializing advanced drug device combination products for the treatment of coronary and peripheral artery disease. The Swiss company's flagship product is the Selution SLR™ DEB, which is a novel sirolimus-eluting balloon platform technology. The CEO of the company is Jeffrey Bryan Jump.

Salubris Biotherapeutics, Inc. is a company that specializes in innovative drug discovery and development. The company is based in Gaithersburg, MD. The company is passionate, committed, and enthusiastic about their work, and value teamwork. The company was founded in 2016. Sam Murphy has been the CEO of the company since 2017.